Multicenter evaluation of efficacy and toxicity of venetoclax‐based combinations in patients with accelerated and blast phase myeloproliferative neoplasms
Gespeichert in:
| Veröffentlicht in: | American journal of hematology 2022-01, Vol.97 (1), p.E7-E10 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | E10 |
|---|---|
| container_issue | 1 |
| container_start_page | E7 |
| container_title | American journal of hematology |
| container_volume | 97 |
| creator | King, Amber C. Weis, Taylor M. Derkach, Andriy Ball, Somedeb Pandey, Manu Mauro, Michael J. Goldberg, Aaron D. Stahl, Maximilian Famulare, Christopher Tallman, Martin S. Wang, Eunice S. Kuykendall, Andrew T. Rampal, Raajit K. |
| description | |
| doi_str_mv | 10.1002/ajh.26381 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2584438052</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2584438052</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3881-88442a2cdd02e70125fb1177eb64cb7f3ff2b8eb6ce353e011a2cc4dc8b424a13</originalsourceid><addsrcrecordid>eNp1kU1uFDEQhS0EIkNgwQWQJTawmMR__TPLKAoEFMQG1pbtLms8crebtnuS3nEEDsDpOAk1mcACiZXL8lfPr-oR8pKzM86YODe77ZmoZcsfkRVnm3rd1pV4TFZM1hxrtjkhz3LeMca5atlTciJV3SixkSvy89McS3AwFJgo7E2cTQlpoMlT8D444xZqho6WdBdcKMvhYQ8DlOSiufv1_Yc1GTrqUm_DcN-aaRjoiCVqZnobypYa5yDCZAqSBzEbTS503GIr7ReIaZxSDP5AhD3QAdKIRJ-fkyfexAwvHs5T8vXd1ZfL6_XN5_cfLi9u1k62LU7YKiWMcF3HBDSMi8pbzpsGbK2cbbz0XtgWbw5kJQG3gLBTnWutEspweUreHHXRx7cZctF9yGg5GrQyZy0q_EG2rBKIvv4H3aV5GtCdFjVrNk3Fa4bU2yPlppTzBF6PU-jNtGjO9CEyjZHp-8iQffWgONseur_kn4wQOD8CtyHC8n8lffHx-ij5G5vTpQ4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2607975160</pqid></control><display><type>article</type><title>Multicenter evaluation of efficacy and toxicity of venetoclax‐based combinations in patients with accelerated and blast phase myeloproliferative neoplasms</title><source>MEDLINE</source><source>Wiley Free Content</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library All Journals</source><creator>King, Amber C. ; Weis, Taylor M. ; Derkach, Andriy ; Ball, Somedeb ; Pandey, Manu ; Mauro, Michael J. ; Goldberg, Aaron D. ; Stahl, Maximilian ; Famulare, Christopher ; Tallman, Martin S. ; Wang, Eunice S. ; Kuykendall, Andrew T. ; Rampal, Raajit K.</creator><creatorcontrib>King, Amber C. ; Weis, Taylor M. ; Derkach, Andriy ; Ball, Somedeb ; Pandey, Manu ; Mauro, Michael J. ; Goldberg, Aaron D. ; Stahl, Maximilian ; Famulare, Christopher ; Tallman, Martin S. ; Wang, Eunice S. ; Kuykendall, Andrew T. ; Rampal, Raajit K.</creatorcontrib><identifier>ISSN: 0361-8609</identifier><identifier>EISSN: 1096-8652</identifier><identifier>DOI: 10.1002/ajh.26381</identifier><identifier>PMID: 34674293</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Bridged Bicyclo Compounds, Heterocyclic - adverse effects ; Bridged Bicyclo Compounds, Heterocyclic - therapeutic use ; Female ; Hematology ; Humans ; Male ; Middle Aged ; Myeloproliferative Disorders - drug therapy ; Retrospective Studies ; Sulfonamides - adverse effects ; Sulfonamides - therapeutic use ; Toxicity ; Treatment Outcome</subject><ispartof>American journal of hematology, 2022-01, Vol.97 (1), p.E7-E10</ispartof><rights>2021 Wiley Periodicals LLC.</rights><rights>2022 Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3881-88442a2cdd02e70125fb1177eb64cb7f3ff2b8eb6ce353e011a2cc4dc8b424a13</citedby><cites>FETCH-LOGICAL-c3881-88442a2cdd02e70125fb1177eb64cb7f3ff2b8eb6ce353e011a2cc4dc8b424a13</cites><orcidid>0000-0002-9040-7415 ; 0000-0002-4333-9624</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fajh.26381$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fajh.26381$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,1432,27923,27924,45573,45574,46408,46832</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34674293$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>King, Amber C.</creatorcontrib><creatorcontrib>Weis, Taylor M.</creatorcontrib><creatorcontrib>Derkach, Andriy</creatorcontrib><creatorcontrib>Ball, Somedeb</creatorcontrib><creatorcontrib>Pandey, Manu</creatorcontrib><creatorcontrib>Mauro, Michael J.</creatorcontrib><creatorcontrib>Goldberg, Aaron D.</creatorcontrib><creatorcontrib>Stahl, Maximilian</creatorcontrib><creatorcontrib>Famulare, Christopher</creatorcontrib><creatorcontrib>Tallman, Martin S.</creatorcontrib><creatorcontrib>Wang, Eunice S.</creatorcontrib><creatorcontrib>Kuykendall, Andrew T.</creatorcontrib><creatorcontrib>Rampal, Raajit K.</creatorcontrib><title>Multicenter evaluation of efficacy and toxicity of venetoclax‐based combinations in patients with accelerated and blast phase myeloproliferative neoplasms</title><title>American journal of hematology</title><addtitle>Am J Hematol</addtitle><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Bridged Bicyclo Compounds, Heterocyclic - adverse effects</subject><subject>Bridged Bicyclo Compounds, Heterocyclic - therapeutic use</subject><subject>Female</subject><subject>Hematology</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Myeloproliferative Disorders - drug therapy</subject><subject>Retrospective Studies</subject><subject>Sulfonamides - adverse effects</subject><subject>Sulfonamides - therapeutic use</subject><subject>Toxicity</subject><subject>Treatment Outcome</subject><issn>0361-8609</issn><issn>1096-8652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kU1uFDEQhS0EIkNgwQWQJTawmMR__TPLKAoEFMQG1pbtLms8crebtnuS3nEEDsDpOAk1mcACiZXL8lfPr-oR8pKzM86YODe77ZmoZcsfkRVnm3rd1pV4TFZM1hxrtjkhz3LeMca5atlTciJV3SixkSvy89McS3AwFJgo7E2cTQlpoMlT8D444xZqho6WdBdcKMvhYQ8DlOSiufv1_Yc1GTrqUm_DcN-aaRjoiCVqZnobypYa5yDCZAqSBzEbTS503GIr7ReIaZxSDP5AhD3QAdKIRJ-fkyfexAwvHs5T8vXd1ZfL6_XN5_cfLi9u1k62LU7YKiWMcF3HBDSMi8pbzpsGbK2cbbz0XtgWbw5kJQG3gLBTnWutEspweUreHHXRx7cZctF9yGg5GrQyZy0q_EG2rBKIvv4H3aV5GtCdFjVrNk3Fa4bU2yPlppTzBF6PU-jNtGjO9CEyjZHp-8iQffWgONseur_kn4wQOD8CtyHC8n8lffHx-ij5G5vTpQ4</recordid><startdate>20220101</startdate><enddate>20220101</enddate><creator>King, Amber C.</creator><creator>Weis, Taylor M.</creator><creator>Derkach, Andriy</creator><creator>Ball, Somedeb</creator><creator>Pandey, Manu</creator><creator>Mauro, Michael J.</creator><creator>Goldberg, Aaron D.</creator><creator>Stahl, Maximilian</creator><creator>Famulare, Christopher</creator><creator>Tallman, Martin S.</creator><creator>Wang, Eunice S.</creator><creator>Kuykendall, Andrew T.</creator><creator>Rampal, Raajit K.</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9040-7415</orcidid><orcidid>https://orcid.org/0000-0002-4333-9624</orcidid></search><sort><creationdate>20220101</creationdate><title>Multicenter evaluation of efficacy and toxicity of venetoclax‐based combinations in patients with accelerated and blast phase myeloproliferative neoplasms</title><author>King, Amber C. ; Weis, Taylor M. ; Derkach, Andriy ; Ball, Somedeb ; Pandey, Manu ; Mauro, Michael J. ; Goldberg, Aaron D. ; Stahl, Maximilian ; Famulare, Christopher ; Tallman, Martin S. ; Wang, Eunice S. ; Kuykendall, Andrew T. ; Rampal, Raajit K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3881-88442a2cdd02e70125fb1177eb64cb7f3ff2b8eb6ce353e011a2cc4dc8b424a13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Bridged Bicyclo Compounds, Heterocyclic - adverse effects</topic><topic>Bridged Bicyclo Compounds, Heterocyclic - therapeutic use</topic><topic>Female</topic><topic>Hematology</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Myeloproliferative Disorders - drug therapy</topic><topic>Retrospective Studies</topic><topic>Sulfonamides - adverse effects</topic><topic>Sulfonamides - therapeutic use</topic><topic>Toxicity</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>King, Amber C.</creatorcontrib><creatorcontrib>Weis, Taylor M.</creatorcontrib><creatorcontrib>Derkach, Andriy</creatorcontrib><creatorcontrib>Ball, Somedeb</creatorcontrib><creatorcontrib>Pandey, Manu</creatorcontrib><creatorcontrib>Mauro, Michael J.</creatorcontrib><creatorcontrib>Goldberg, Aaron D.</creatorcontrib><creatorcontrib>Stahl, Maximilian</creatorcontrib><creatorcontrib>Famulare, Christopher</creatorcontrib><creatorcontrib>Tallman, Martin S.</creatorcontrib><creatorcontrib>Wang, Eunice S.</creatorcontrib><creatorcontrib>Kuykendall, Andrew T.</creatorcontrib><creatorcontrib>Rampal, Raajit K.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>King, Amber C.</au><au>Weis, Taylor M.</au><au>Derkach, Andriy</au><au>Ball, Somedeb</au><au>Pandey, Manu</au><au>Mauro, Michael J.</au><au>Goldberg, Aaron D.</au><au>Stahl, Maximilian</au><au>Famulare, Christopher</au><au>Tallman, Martin S.</au><au>Wang, Eunice S.</au><au>Kuykendall, Andrew T.</au><au>Rampal, Raajit K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Multicenter evaluation of efficacy and toxicity of venetoclax‐based combinations in patients with accelerated and blast phase myeloproliferative neoplasms</atitle><jtitle>American journal of hematology</jtitle><addtitle>Am J Hematol</addtitle><date>2022-01-01</date><risdate>2022</risdate><volume>97</volume><issue>1</issue><spage>E7</spage><epage>E10</epage><pages>E7-E10</pages><issn>0361-8609</issn><eissn>1096-8652</eissn><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>34674293</pmid><doi>10.1002/ajh.26381</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0002-9040-7415</orcidid><orcidid>https://orcid.org/0000-0002-4333-9624</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0361-8609 |
| ispartof | American journal of hematology, 2022-01, Vol.97 (1), p.E7-E10 |
| issn | 0361-8609 1096-8652 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2584438052 |
| source | MEDLINE; Wiley Free Content; EZB-FREE-00999 freely available EZB journals; Wiley Online Library All Journals |
| subjects | Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bridged Bicyclo Compounds, Heterocyclic - adverse effects Bridged Bicyclo Compounds, Heterocyclic - therapeutic use Female Hematology Humans Male Middle Aged Myeloproliferative Disorders - drug therapy Retrospective Studies Sulfonamides - adverse effects Sulfonamides - therapeutic use Toxicity Treatment Outcome |
| title | Multicenter evaluation of efficacy and toxicity of venetoclax‐based combinations in patients with accelerated and blast phase myeloproliferative neoplasms |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T14%3A10%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Multicenter%20evaluation%20of%20efficacy%20and%20toxicity%20of%20venetoclax%E2%80%90based%20combinations%20in%20patients%20with%20accelerated%20and%20blast%20phase%20myeloproliferative%20neoplasms&rft.jtitle=American%20journal%20of%20hematology&rft.au=King,%20Amber%20C.&rft.date=2022-01-01&rft.volume=97&rft.issue=1&rft.spage=E7&rft.epage=E10&rft.pages=E7-E10&rft.issn=0361-8609&rft.eissn=1096-8652&rft_id=info:doi/10.1002/ajh.26381&rft_dat=%3Cproquest_cross%3E2584438052%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2607975160&rft_id=info:pmid/34674293&rfr_iscdi=true |